Nucleus Genomic is a genetic testing service provider that focuses on analyzing the risk of certain diseases in patients. Provides a comprehensive assessment of genetic predisposition for countless diseases and traits by combining polygenic scoring with traditional rare variant DNA analysis. Nucleus provides users with WGS genetic testing kits for rare variant analysis and polygenic scoring of diseases ranging from breast cancer risk to longevity propensity. Recently, Nucleus Genomics announced that it has raised $14 million in seed+ financing led by Alexis Ohanian’s Seven Seven Six. Investors include Ohanian, Founders Fund, Adrian Aoun, Brent Saunders, Matteo Franceschetti and more.
This article is reproduced from: https://www.itjuzi.com/investevent/13361424
This site is for inclusion only, and the copyright belongs to the original author.